The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Accupril® (Quinapril HCl Tablets), 10 mg

Accupril® (Quinapril HCl Tablets), 20 mg

Accupril® (Quinapril HCl Tablets), 40 mg

NDC	Lot Number	Expiration Date	Strength	Configuration/Count
0071-0530-23	DR9639	2023 MAR 31	10 mg	1 x 90 count bottle
0071-0532-23	DX8682	2023 MAR 31	20 mg	1 x 90 count bottle
	DG1188	2022 MAY 31	20 mg	1 x 90 count bottle
0071-0535-23	DX6031	2023 MAR 31	40mg	1 x 90 count bottle
	CK6260	2022 MAY 31	40mg	1 x 90 count bottle

Pfizer Inc. is recalling the above referenced lots of **Accupril® (Quinapril HCl Tablets).** Pfizer initiated this recall due to the presence of n-nitroso-quinapril above the Acceptable Daily Intake (ADI) level. Pfizer conducted a toxicological evaluation to establish an ADI, which incorporated numerous conservative assumptions. Pfizer also conducted a Product Assessment, including an evaluation of safety surveillance data. Based on Pfizer's assessments, the benefit/risk of quinapril remains positive based on currently available data. Although a potential excess lifetime cancer risk from n-nitroso-quinapril may exist, it is considered to be low based on currently available data.

The recall of the above referenced lots of **Accupril® (Quinapril HCl Tablets)** is being conducted to the **Consumer/User level.**